カテゴリー： QYResearch, 世界, 医療/バイオ

世界の長時間作用型可逆性避妊薬（LARC）市場インサイト及び予測（ホルモン性子宮内避妊器具、銅子宮内避妊器具、避妊用インプラント、その他）

◆英語タイトル：Global Long-acting Reversible Contraceptives (LARCs) Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JLX09670）◆商品コード：QY22JLX09670
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：117
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、長時間作用型可逆性避妊薬（LARC）のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に長時間作用型可逆性避妊薬（LARC）の世界市場のxxx％を占める「ホルモン性子宮内避妊器具」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「20〜24歳」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
長時間作用型可逆性避妊薬（LARC）の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの長時間作用型可逆性避妊薬（LARC）市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

長時間作用型可逆性避妊薬（LARC）のグローバル主要企業には、Bayer、Merck、Cooper Companies、AbbVie Allergan、Yantai JiShengYaoXie、H & J Medical、HRA Pharma、Pregna、ASPIVIX、Shanghai Dahua Pharmaceuticals、Williams Medical Supplies、Laboratoire 7 MED、Durbin、Laboratoire CCD、Prosan、OCONなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

長時間作用型可逆性避妊薬（LARC）市場は、種類と用途によって区分されます。世界の長時間作用型可逆性避妊薬（LARC）市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ホルモン性子宮内避妊器具、銅子宮内避妊器具、避妊用インプラント、その他

【用途別セグメント】
20〜24歳、25〜34歳、35〜44歳、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 長時間作用型可逆性避妊薬（LARC）製品概要
- 種類別市場（ホルモン性子宮内避妊器具、銅子宮内避妊器具、避妊用インプラント、その他）
- 用途別市場（20〜24歳、25〜34歳、35〜44歳、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の長時間作用型可逆性避妊薬（LARC）販売量予測2017-2028
- 世界の長時間作用型可逆性避妊薬（LARC）売上予測2017-2028
- 長時間作用型可逆性避妊薬（LARC）の地域別販売量
- 長時間作用型可逆性避妊薬（LARC）の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別長時間作用型可逆性避妊薬（LARC）販売量
- 主要メーカー別長時間作用型可逆性避妊薬（LARC）売上
- 主要メーカー別長時間作用型可逆性避妊薬（LARC）価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ホルモン性子宮内避妊器具、銅子宮内避妊器具、避妊用インプラント、その他）
- 長時間作用型可逆性避妊薬（LARC）の種類別販売量
- 長時間作用型可逆性避妊薬（LARC）の種類別売上
- 長時間作用型可逆性避妊薬（LARC）の種類別価格
・用途別市場規模（20〜24歳、25〜34歳、35〜44歳、その他）
- 長時間作用型可逆性避妊薬（LARC）の用途別販売量
- 長時間作用型可逆性避妊薬（LARC）の用途別売上
- 長時間作用型可逆性避妊薬（LARC）の用途別価格
・北米市場
- 北米の長時間作用型可逆性避妊薬（LARC）市場規模（種類別、用途別）
- 主要国別の長時間作用型可逆性避妊薬（LARC）市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの長時間作用型可逆性避妊薬（LARC）市場規模（種類別、用途別）
- 主要国別の長時間作用型可逆性避妊薬（LARC）市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の長時間作用型可逆性避妊薬（LARC）市場規模（種類別、用途別）
- 主要国別の長時間作用型可逆性避妊薬（LARC）市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の長時間作用型可逆性避妊薬（LARC）市場規模（種類別、用途別）
- 主要国別の長時間作用型可逆性避妊薬（LARC）市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの長時間作用型可逆性避妊薬（LARC）市場規模（種類別、用途別）
- 主要国別の長時間作用型可逆性避妊薬（LARC）市場規模（トルコ、サウジアラビア）
・企業情報
Bayer、Merck、Cooper Companies、AbbVie Allergan、Yantai JiShengYaoXie、H & J Medical、HRA Pharma、Pregna、ASPIVIX、Shanghai Dahua Pharmaceuticals、Williams Medical Supplies、Laboratoire 7 MED、Durbin、Laboratoire CCD、Prosan、OCON
・産業チェーン及び販売チャネル分析
- 長時間作用型可逆性避妊薬（LARC）の産業チェーン分析
- 長時間作用型可逆性避妊薬（LARC）の原材料
- 長時間作用型可逆性避妊薬（LARC）の生産プロセス
- 長時間作用型可逆性避妊薬（LARC）の販売及びマーケティング
- 長時間作用型可逆性避妊薬（LARC）の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 長時間作用型可逆性避妊薬（LARC）の産業動向
- 長時間作用型可逆性避妊薬（LARC）のマーケットドライバー
- 長時間作用型可逆性避妊薬（LARC）の課題
- 長時間作用型可逆性避妊薬（LARC）の阻害要因
・主な調査結果

Market Analysis and Insights: Global Long-acting Reversible Contraceptives (LARCs) Market
Due to the COVID-19 pandemic, the global Long-acting Reversible Contraceptives (LARCs) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Hormonal Intrauterine Devices accounting for % of the Long-acting Reversible Contraceptives (LARCs) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Age 20-24 segment is altered to an % CAGR throughout this forecast period.
China Long-acting Reversible Contraceptives (LARCs) market size is valued at US$ million in 2021, while the US and Europe Long-acting Reversible Contraceptives (LARCs) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Long-acting Reversible Contraceptives (LARCs) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Long-acting Reversible Contraceptives (LARCs) include Bayer, Merck, Cooper Companies, AbbVie Allergan, Yantai JiShengYaoXie, H & J Medical, HRA Pharma, Pregna and ASPIVIX, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Long-acting Reversible Contraceptives (LARCs) Scope and Segment
Long-acting Reversible Contraceptives (LARCs) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Long-acting Reversible Contraceptives (LARCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hormonal Intrauterine Devices
Copper Intrauterine Devices
Contraceptive Implants
Others
Segment by Application
Age 20-24
Age 25-34
Age 35-44
Others
By Company
Bayer
Merck
Cooper Companies
AbbVie Allergan
Yantai JiShengYaoXie
H & J Medical
HRA Pharma
Pregna
ASPIVIX
Shanghai Dahua Pharmaceuticals
Williams Medical Supplies
Laboratoire 7 MED
Durbin
Laboratoire CCD
Prosan
OCON
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Long-acting Reversible Contraceptives (LARCs) Product Introduction
1.2 Market by Type
1.2.1 Global Long-acting Reversible Contraceptives (LARCs) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hormonal Intrauterine Devices
1.2.3 Copper Intrauterine Devices
1.2.4 Contraceptive Implants
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long-acting Reversible Contraceptives (LARCs) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Age 20-24
1.3.3 Age 25-34
1.3.4 Age 35-44
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Estimates and Forecasts 2017-2028
2.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue Estimates and Forecasts 2017-2028
2.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region
2.4.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region (2017-2022)
2.4.2 Global Sales Long-acting Reversible Contraceptives (LARCs) by Region (2023-2028)
2.5 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region
2.5.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region (2017-2022)
2.5.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Manufacturers
3.1.1 Global Top Long-acting Reversible Contraceptives (LARCs) Manufacturers by Sales (2017-2022)
3.1.2 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Long-acting Reversible Contraceptives (LARCs) in 2021
3.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Manufacturers
3.2.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Manufacturers (2017-2022)
3.2.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Long-acting Reversible Contraceptives (LARCs) Revenue in 2021
3.3 Global Long-acting Reversible Contraceptives (LARCs) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Long-acting Reversible Contraceptives (LARCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Long-acting Reversible Contraceptives (LARCs) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Type
4.1.1 Global Long-acting Reversible Contraceptives (LARCs) Historical Sales by Type (2017-2022)
4.1.2 Global Long-acting Reversible Contraceptives (LARCs) Forecasted Sales by Type (2023-2028)
4.1.3 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Type (2017-2028)
4.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Type
4.2.1 Global Long-acting Reversible Contraceptives (LARCs) Historical Revenue by Type (2017-2022)
4.2.2 Global Long-acting Reversible Contraceptives (LARCs) Forecasted Revenue by Type (2023-2028)
4.2.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Type (2017-2028)
4.3 Global Long-acting Reversible Contraceptives (LARCs) Price by Type
4.3.1 Global Long-acting Reversible Contraceptives (LARCs) Price by Type (2017-2022)
4.3.2 Global Long-acting Reversible Contraceptives (LARCs) Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Application
5.1.1 Global Long-acting Reversible Contraceptives (LARCs) Historical Sales by Application (2017-2022)
5.1.2 Global Long-acting Reversible Contraceptives (LARCs) Forecasted Sales by Application (2023-2028)
5.1.3 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Application (2017-2028)
5.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Application
5.2.1 Global Long-acting Reversible Contraceptives (LARCs) Historical Revenue by Application (2017-2022)
5.2.2 Global Long-acting Reversible Contraceptives (LARCs) Forecasted Revenue by Application (2023-2028)
5.2.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Application (2017-2028)
5.3 Global Long-acting Reversible Contraceptives (LARCs) Price by Application
5.3.1 Global Long-acting Reversible Contraceptives (LARCs) Price by Application (2017-2022)
5.3.2 Global Long-acting Reversible Contraceptives (LARCs) Price Forecast by Application (2023-2028)
6 North America
6.1 North America Long-acting Reversible Contraceptives (LARCs) Market Size by Type
6.1.1 North America Long-acting Reversible Contraceptives (LARCs) Sales by Type (2017-2028)
6.1.2 North America Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2017-2028)
6.2 North America Long-acting Reversible Contraceptives (LARCs) Market Size by Application
6.2.1 North America Long-acting Reversible Contraceptives (LARCs) Sales by Application (2017-2028)
6.2.2 North America Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2017-2028)
6.3 North America Long-acting Reversible Contraceptives (LARCs) Market Size by Country
6.3.1 North America Long-acting Reversible Contraceptives (LARCs) Sales by Country (2017-2028)
6.3.2 North America Long-acting Reversible Contraceptives (LARCs) Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Long-acting Reversible Contraceptives (LARCs) Market Size by Type
7.1.1 Europe Long-acting Reversible Contraceptives (LARCs) Sales by Type (2017-2028)
7.1.2 Europe Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2017-2028)
7.2 Europe Long-acting Reversible Contraceptives (LARCs) Market Size by Application
7.2.1 Europe Long-acting Reversible Contraceptives (LARCs) Sales by Application (2017-2028)
7.2.2 Europe Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2017-2028)
7.3 Europe Long-acting Reversible Contraceptives (LARCs) Market Size by Country
7.3.1 Europe Long-acting Reversible Contraceptives (LARCs) Sales by Country (2017-2028)
7.3.2 Europe Long-acting Reversible Contraceptives (LARCs) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Market Size by Type
8.1.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales by Type (2017-2028)
8.1.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2017-2028)
8.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Market Size by Application
8.2.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales by Application (2017-2028)
8.2.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2017-2028)
8.3 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Market Size by Region
8.3.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales by Region (2017-2028)
8.3.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Long-acting Reversible Contraceptives (LARCs) Market Size by Type
9.1.1 Latin America Long-acting Reversible Contraceptives (LARCs) Sales by Type (2017-2028)
9.1.2 Latin America Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2017-2028)
9.2 Latin America Long-acting Reversible Contraceptives (LARCs) Market Size by Application
9.2.1 Latin America Long-acting Reversible Contraceptives (LARCs) Sales by Application (2017-2028)
9.2.2 Latin America Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2017-2028)
9.3 Latin America Long-acting Reversible Contraceptives (LARCs) Market Size by Country
9.3.1 Latin America Long-acting Reversible Contraceptives (LARCs) Sales by Country (2017-2028)
9.3.2 Latin America Long-acting Reversible Contraceptives (LARCs) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Market Size by Type
10.1.1 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales by Type (2017-2028)
10.1.2 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2017-2028)
10.2 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Market Size by Application
10.2.1 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales by Application (2017-2028)
10.2.2 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2017-2028)
10.3 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Market Size by Country
10.3.1 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales by Country (2017-2028)
10.3.2 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Overview
11.1.3 Bayer Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bayer Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Cooper Companies
11.3.1 Cooper Companies Corporation Information
11.3.2 Cooper Companies Overview
11.3.3 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cooper Companies Recent Developments
11.4 AbbVie Allergan
11.4.1 AbbVie Allergan Corporation Information
11.4.2 AbbVie Allergan Overview
11.4.3 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AbbVie Allergan Recent Developments
11.5 Yantai JiShengYaoXie
11.5.1 Yantai JiShengYaoXie Corporation Information
11.5.2 Yantai JiShengYaoXie Overview
11.5.3 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Yantai JiShengYaoXie Recent Developments
11.6 H & J Medical
11.6.1 H & J Medical Corporation Information
11.6.2 H & J Medical Overview
11.6.3 H & J Medical Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 H & J Medical Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 H & J Medical Recent Developments
11.7 HRA Pharma
11.7.1 HRA Pharma Corporation Information
11.7.2 HRA Pharma Overview
11.7.3 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 HRA Pharma Recent Developments
11.8 Pregna
11.8.1 Pregna Corporation Information
11.8.2 Pregna Overview
11.8.3 Pregna Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pregna Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pregna Recent Developments
11.9 ASPIVIX
11.9.1 ASPIVIX Corporation Information
11.9.2 ASPIVIX Overview
11.9.3 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 ASPIVIX Recent Developments
11.10 Shanghai Dahua Pharmaceuticals
11.10.1 Shanghai Dahua Pharmaceuticals Corporation Information
11.10.2 Shanghai Dahua Pharmaceuticals Overview
11.10.3 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai Dahua Pharmaceuticals Recent Developments
11.11 Williams Medical Supplies
11.11.1 Williams Medical Supplies Corporation Information
11.11.2 Williams Medical Supplies Overview
11.11.3 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Williams Medical Supplies Recent Developments
11.12 Laboratoire 7 MED
11.12.1 Laboratoire 7 MED Corporation Information
11.12.2 Laboratoire 7 MED Overview
11.12.3 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Laboratoire 7 MED Recent Developments
11.13 Durbin
11.13.1 Durbin Corporation Information
11.13.2 Durbin Overview
11.13.3 Durbin Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Durbin Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Durbin Recent Developments
11.14 Laboratoire CCD
11.14.1 Laboratoire CCD Corporation Information
11.14.2 Laboratoire CCD Overview
11.14.3 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Laboratoire CCD Recent Developments
11.15 Prosan
11.15.1 Prosan Corporation Information
11.15.2 Prosan Overview
11.15.3 Prosan Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Prosan Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Prosan Recent Developments
11.16 OCON
11.16.1 OCON Corporation Information
11.16.2 OCON Overview
11.16.3 OCON Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 OCON Long-acting Reversible Contraceptives (LARCs) Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 OCON Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Long-acting Reversible Contraceptives (LARCs) Industry Chain Analysis
12.2 Long-acting Reversible Contraceptives (LARCs) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Long-acting Reversible Contraceptives (LARCs) Production Mode & Process
12.4 Long-acting Reversible Contraceptives (LARCs) Sales and Marketing
12.4.1 Long-acting Reversible Contraceptives (LARCs) Sales Channels
12.4.2 Long-acting Reversible Contraceptives (LARCs) Distributors
12.5 Long-acting Reversible Contraceptives (LARCs) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Long-acting Reversible Contraceptives (LARCs) Industry Trends
13.2 Long-acting Reversible Contraceptives (LARCs) Market Drivers
13.3 Long-acting Reversible Contraceptives (LARCs) Market Challenges
13.4 Long-acting Reversible Contraceptives (LARCs) Market Restraints
14 Key Findings in The Global Long-acting Reversible Contraceptives (LARCs) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の長時間作用型可逆性避妊薬（LARC）市場インサイト及び予測（ホルモン性子宮内避妊器具、銅子宮内避妊器具、避妊用インプラント、その他）(Global Long-acting Reversible Contraceptives (LARCs) Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 即効性喘息治療薬のグローバル市場2023年：錠剤、スプレー
  • 世界の長時間作用型スルホンアミド市場インサイト及び予測（腸管吸収、腸管難吸収、外用）
  • 世界の超長時間作用性ベータ刺激薬市場インサイト及び予測（液体、錠剤）
  • 世界の長時間作用型薬物送達市場インサイト及び予測（装置、非経口注射）
  • 世界の超短時間作用型バルビツール酸塩市場インサイト及び予測（メトヘキシタール、チアミラール、チオペンタール）